Bio News
MapLight’s schizophrenia drug showed a 4.5-point improvement in PANSS scores in a phase 2 trial, but its market value plunged 67%. CEO Kroger emphasized the drug’s competitiveness, saying its effect size was similar to Cobenfy’s and citing an odds ratio of 2.8 for readiness for discharge. All patients reached the target dose, and signals of cognitive improvement were also observed. The drug’s development will expand into a clinical trial for psychosis in Alzheimer disease.
BIOBOOK TEAM
biobookmedia@biobook.co.krRural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
HLB Submits FDA Resubmission for First-Line Liver Cancer Treatment
Celltrion Reports Third-Quarter Revenue of 1.5 Trillion Won and Operating Profit of 510 Billion Won, Up 69% Year Over Year
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
